Key Highlights

  • agilon health (NYSE:AGL) fell about 21% on November 18, 2026, trading near USD 115 after a 1-for-25 Reverse Stock Split earlier this year that explains its high share price.
  • No company-specific announcement was found; the decline came as Humana fell 12.98% and UnitedHealth 10.21% on a proposed Medicare Advantage audit rule.
  • The company reported third-quarter adjusted EPS of USD 1.97 against an expected loss and Revenue of USD 1.51 billion, and raised 2026 adjusted EBITDA guidance to USD 145 million to USD 155 million.
  • An analyst reiterated a hold rating with a USD 112 target on November 18, close to the level where the stock traded.

Caught in the Medicare Advantage Sell-Off

agilon health (NYSE:AGL) partners with primary care physicians to manage the health of Medicare Advantage patients under value-based contracts, sharing in savings and losses on their medical costs. That model ties its fortunes closely to the Economics of Medicare Advantage, which came under intense pressure this week. On November 16, the Department of Health and Human Services proposed a rule that would extrapolate audit error rates from sampled patient records to entire Medicare Advantage contracts, starting with 2018 payments. The government estimates recoveries of about USD 90.2 billion between 2027 and 2036. Insurers sold off for a second day on November 18, with Humana down 12.98%, UnitedHealth down 10.21%, Elevance down 7.63% and Centene down 7.03%. Health care was the second-worst sector in the S&P 500, falling 2.20%. No company-specific news explaining agilon's decline of about 21% was found, so the link to the proposed rule is an inference based on timing and Business exposure. Lower payments to insurers could, over time, pressure the funding available to provider partners like agilon, which helps explain why investors sold the stock alongside the insurers.

A Strong Quarter Overshadowed

The decline came despite solid recent results. For the third quarter, agilon reported adjusted Earnings of USD 1.97 per share, compared with an expected loss of USD 1.22, and revenue of USD 1.51 billion, ahead of the USD 1.46 billion consensus. The company raised its 2026 adjusted EBITDA guidance to USD 145 million to USD 155 million, well above the previous midpoint of about USD 85 million. Management has focused on clinical programme discipline and lowering per-member medical costs, which have improved margins after a difficult period. The share price looks unusual for a company of its size because of a 1-for-25 reverse split that took effect on March 30, 2026, carried out to lift the price above USD 1.00 and keep its New York Stock Exchange listing. An analyst reiterated a hold rating and a USD 112 target on November 18, noting progress on costs, with the stock trading near USD 115 at the time.

What Comes Next

The proposed rule will be published in the Federal Register on November 19, opening a comment period that runs until January 19, 2027. Insurers and provider groups are expected to push back, and a federal court in Texas previously set aside similar provisions of a 2023 rule on procedural grounds, so the final outcome is uncertain. For agilon, the key questions are how its contracts with insurers allocate any recovered payments and whether future rates paid to providers will be squeezed. Investors will also watch fourth-quarter results and 2027 guidance for signs that cost improvements are sustainable. Until the regulatory picture becomes clearer, the stock is likely to trade with Medicare Advantage insurers rather than on its own operating progress.

Where Things Stand

agilon health (NYSE:AGL) fell about 21% as Medicare Advantage stocks slumped on a proposed CMS audit rule, despite strong third-quarter results and raised guidance. The comment period to January 19, 2027 will shape the outlook.